In the race to the Covid-19 vaccine, the progress that has now led to New Zealand’s first jab on Friday has seen several of the biotech world’s largest players fall flat, while others that had never had a vaccine approved before have rocketed into the global consciousness.
Shares in GSK,
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
